The 10 drugs that cost Medicare Part B the most in 2018, according to a Moody’s Investors Service report:
- Eylea (Regeneron) — $2.57 billion
- Keytruda (Merck) — $1.81 billion
- Opdivo (Bristol-Myers Squibb) — $1.72 billion
- Rituxan (Roche) — $1.70 billion
- Prolia (Amgen) — $1.42 billion
- Neulasta (Amgen) — $1.37 billion
- Lucentis (Roche) — $1.22 billion
- Remicade (Johnson & Johnson) — $1.15 billion
- Avastin (Roche) — $1.01 billion
- Herceptin (Roche) — $822 million
More articles on pharmacy:
CVS offering emergency prescriptions in Puerto Rico
IPO of joint venture with Pfizer not discussed, GlaxoSmithKline says
Civica Rx inks deal to create its own drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.